Skip to main
MRK

Merck (MRK) Stock Forecast & Price Target

Merck (MRK) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 27%
Buy 45%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

Merck & Co is well positioned for growth in the coming years due to a strong portfolio of products targeting diverse therapeutic areas, including cancer, cardiometabolic disease, and infections. The company's leading immuno-oncology platform, Keytruda, is a major contributor to its overall sales and has a high probability of success in various indications, including adjuvant melanoma. Additionally, the company's strong pipeline, with notable programs such as enlicitide and islatravir, supports its growth potential beyond 2028 when Keytruda is expected to face competition. Management's focus on sustainability and diversity initiatives further strengthens the company's long-term outlook.

Bears say

Merck & Co is facing a significant loss in revenue with the impending loss of exclusivity for their top-selling drug, Keytruda, in 2028. While they have a diversified pipeline, their success in replacing Keytruda revenue is uncertain, especially with the recent failure of their Wnt agonist, MK-3000, in diabetic macular edema. Additionally, Merck faces significant risks from their reliance on top pipeline assets, the impact of climate change, and regulatory pressures. This, combined with their high valuation, presents a challenging outlook for the company.

Merck (MRK) has been analyzed by 22 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 45% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merck (MRK) Forecast

Analysts have given Merck (MRK) a Buy based on their latest research and market trends.

According to 22 analysts, Merck (MRK) has a Buy consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $150.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $150.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merck (MRK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.